MONDAY 23 MARCH

08.00h Registration
09.00h Opening of the Workshop

Session 1 How to select the right drug and the right dose for the individual patient

Chairs: Howard Gurney and Nielka van Erp

09.15h Pharmacology as a tool to dose individualize cancer therapy
Mark Ratain, MD, University of Chicago, USA

09.45h Early biomarkers as a tool to dose individualize cancer therapy
Timothy Yap, MD, PhD, Institute of Cancer Research, United Kingdom

10.15h Discussion

10.45h Coffee Break

Session 2 Approaches to dose individualize/optimize cancer therapeutics

Chairs: Howard Gurney and Nielka van Erp

11.15h Obstacles to use dose optimization in an early stage of cancer drug development
René Bruno, PhD, Pharsight, France

B. Lum 0_1

12.00h Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer
G. Bjarnason 0_2

12.15h Toxicity-adjusted dose (TAD) of sunitinib gives low intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC)
C. Lee 0_3

12.30h Individualized pharmacokinetically-guided dosing of pazopanib: A feasibility study in cancer patients
S. Bins 0_4

12.45h Discussion
13.00h Lunch

Session 3 Dose individualization is commonly and successfully used in other diseases - what can we learn?

Chairs: Mark Ratain and Ron Mathijsen

14.00h The revenues of dose individualization in other disciplines: HIV therapy
Courtney Fletcher, PharmD, University of Nebraska, USA

14.30h Is cancer different? The first steps to dose individualize and optimize anticancer therapy
George Demetri, MD, Harvard Medical School, USA

15.00h Discussion
15.30h      Coffee Break

Session 4  Abstract-driven presentations

Chairs:     Mark Ratain and Ron Mathijssen

16.00h      Optimal TDM and pharmacodynamics of mitotane in adrenocortical cancer in children and adults
            S. Ackland  0_5

16.00h      Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring - The TADE Study.
            H. Gurney   0_6

16.00h      First intra-patient comparison of antidepressant use among tamoxifen patients
            L. Binkhorst 0_7

16.00h      Everolimus exposure strongly related to dose reductions and mucositis: results of a phase II study in patients with thyroid cancer
            D. De Wit   0_8

Session 5  Mini-orals

17.00h      Marker of bevacizumab efficacy: Which place for the pharmacokinetics?
            C. Serdjebi  M_13

17.00h      Tyrosine Kinase Inhibitor (TKI) new oncology drug approvals in the United States from 2010 to 2013- A case of turning a blind eye to the optimal dose at the MTD?
            B. Lum      M_14

17.00h      Distinguishing safety response of a chemo–radium-223 combination using a model-based analysis of an individual cross-over design
            A. Solms    M_15

17.00h      Microdosing as a pharmacokinetic assessment tool to optimize dosing in children
            W. Vaes     M_16

17.00h      Dried blood spot sampling for therapeutic drug monitoring of pazopanib.
            D. De Wit   M_17

17.00h      Polymorphisms of nr1i2 and nr1i3 affect sorafenib and imatinib in vitro activity
            L. Mbatchi  M_18

17.00h      Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions
            R. van Leeuwen M_20

18.00h      Adjournment

TUESDAY 24 MARCH

Session 6  Modeling as a tool to individualize the dose and to accelerate drug approval

Chairs:     Etienne Chatelut and Michelle Rudek

08.30h      Preclinical modeling [PB/PK modeling] as a tool for dose optimization and estimate the clinical relevance of drug interactions
            Joga Gobburu, PhD, FCP, MBA, University of Maryland, USA
## PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09.00h  | The use of PK/PD modeling early in drug development and for dose individualizing approaches  
**Lena Friberg, PharmD, PhD**, Uppsala University, Sweden |
| 09.30h  | Pro-Con Discussion                                                   |
| 10.30h  | Coffee break & poster viewing                                        |

### Session 7  Abstract-driven presentations: Modeling and simulation approaches in oncology and drug interaction studies

**Chairs:** Etienne Chatelut and Michelle Rudek

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 11.30h  | PKPD modeling of individual lesion maximal standardized uptake value in gastrointestinal stromal tumor (GIST) patients treated with sunitinib  
**E. Schindler** O_9 |
| 11.45h  | Population PKPD modeling of abexinostat-induced thrombocytopenia in phase I and application for the determination of the dose/toxicity relationship  
**S. Fouliard** O_10 |
| 12.00h  | A pre-clinical PKPD framework for biomarker led decision making for prioritising dose and schedules for anti-cancer agents to test in the clinic  
**R. Jones** O_11 |
| 12.15h  | Mixed-effect modeling frameworks to optimize treatment of low-grade glioma patients, on population and individual levels  
**P. Mazzocco** O_12 |
| 12.30h  | Group picture                                                               |
| 13.00h  | Lunch                                                                       |

### Session 8

**Chairs:** George Demetri and Howard Gurney

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 14.00h  | Incorporation of dose individualizing approaches in the treatment of cancer – can we learn from the successes in ALL. How will this apply for solid tumors?  
**Jan Schellens, MD, PhD**, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, the Netherlands |
| 14.30h  | Panel Discussion                                                            |
| 15.30h  | Closure of the workshop                                                     |